Tamoxifen Delivery to Breast Cancer Cells (MCF-7) Via Hydroxyapatite Microspheres

Year 2022, Volume: 5 Issue: (Ek sayı 1), 111 - 118, 30.12.2022

Binnaz Kırbıyık Birgül Mazmancı , Şeyma Gülnaz Yarlılar , Naz Uğur Kasım Ocakoğlu

https://doi.org/10.46239/ejbcs.1040161

Cited By: 1

Abstract

Drug delivery systems have been used in cancer treatment to increase drug effectiveness. The hydroxyapatite (HAP) based materials used in this area can provide drug transport to the target site without its deterioration. In this study, porous hollow hydroxyapatite microspheres (PHHMs) were produced by using the hydrothermal method. Tamoxifen (TAM) used in the treatment of breast cancer has been covalently attached to the produced microspheres. The obtained microsphere structures (tamoxifen-loaded hydroxyapatite, TAM/H) were successfully characterized by ATR-FTIR, FE-SEM, XRD, and DLS methods. The breast cancer cell line MCF-7 was used to examine the effect of the hybrid structure. The cytotoxic and genotoxic effects of TAM/H was compared with the TAM groups on MCF-7. Our results have showed that, the decrease in cell viability at 24 and 36 hours were still continued at 48 hours only in TAM/H groups. In addition, TAM/H was found to show a genotoxic affect by the increment in genetic damage index (GDI) and damaged cell percentage (DCP%). As a result, use of hydroxyapatite was suitable for the transport of TAM and that covalent binding was suitable for drug particle interaction with hybrid structure and thus controlled drug release occurred.

Keywords

Hydroxyapatite microsphere, Tamoxifen, Hydrothermal method, MCF-7, Cytotoxicity, Genotoxicity

Supporting Institution

Mersin Üniversitesi

Project Number

2017-1-TP2-2232

Thanks

This work was supported by Mersin University Scientific Research Project Unit (grant no 2017-1-TP2-2232)

References

• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J for Clin. 2001. 51(1): 15-36.
• Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Targed Ther. 2018. 3:7.
• Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front. Mol. Biosci. 2020. https://doi.org/10.3389/fmolb.2020.00193.
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotech. 2015. 33(9): 941-951.
• Singh SK, SinghS, Lillard JWJr, Singh R. Drug delivery approaches for breast cancer. Inter J Nanomed 2017. 12: 6205–6218.
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations. 2008. 26: 57–64.
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Cont Rel. 2000. 65(1–2): 271–284.
• Allen TM. Ligand-targeted therapeutıcs in anticancer therapy. Nat Review Cancer. 2002. 2(10): 750-763.
• Jafari S, Adibkia K. Application of Hydroxyapatite Nanoparticle in the Drug Delivery Systems. J Mol Phar Org Pro Reserch. 2014. 03: 01.
• Hench LL, J. Wilson J. An Introduction to Bioceramics. World Scientific Publishing Co. 1993. 139-189.
• Pasinli A. Biyomedikal alanlarda kullanılan biyomalzemeler. Makine Teknolojileri Elektronik Dergisi. 2004. 4: 25-34.
• Netz DJA, Sepulveda P, Pandolfelli VC, Spadaro ACC, Alencastre JB, Bentley MVLB, Marchetti JM. Potential use of gelcasting hydroxyapatite porous ceramic as an implantable drug delivery system, International Journal of Pharmaceutics. 2001. 213(1-2): 117-125.
• Uskokovic V, Desai TA. In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis. J Phar Sci. 2014. 103(2): 567-579.
• Andres NC, Sieben JM, Baldini M, Rodriguez CH, Famiglietti A, Messina PV. Electroactive Mg2+-Hydroxyapatite Nanostructured Networks against Drug-Resistant Bone Infection Strains. ACS Appl Mater Interfaces. 2018.
• Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000. 64(2): 165-7.
• Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007. 14: 995-998.
• Carlson RW, Hudis CA, Pritchard KI. Adjuvant endocrine therapy for hormone receptor-positive breast cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations. J Nat Comp Cancer Network. 2006. 4(10): 971-979.
• Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin W M, Vogel V. Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Nat Cancer Ins. 1998. 90: 1371–1388.
• Lai W, Chen C, Ren X, In-Seop L, Jiang G, Kong X. Hydrothermal fabrication of porous holl9ow hydroxyapatite microspheres for a drug delivery system. Mat Sci Eng C. 2016. 62: 166–172.
• Garcia SN, Gutierrez L, McNulty A. Real-time cellular analysis as a novel approach for in vitro cytotoxicity testing of medical device extracts. J Biomed Mater Res A. 2013. 101: 2097-2106.
• Şener LT, Albeniz G, Dinç B, Albeniz I. iCELLigence real time cell analysis system for examining the cytotoxicity of drugs to cancer cell lines. Exp Therap Med. 2017. 14: 1866-1870.
• Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu J-C, Sasaki YF. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Env Mol Mut. 2000. 35: 206–221.
• Çavaş T. In vivo genotoxicity evauation of atrizine and atrizine-based herbicide on fish Carassiu auratus using the micronucleus test and the comet assay. Food Chem Tox. 2011. 49: 1431-1435.
• Wu Q, Shi J, Wei J, Yang L, Cao S. In situ functionalization of hollow mesoporous hydroxyapatite with thermal-responsive on-off gates in supercritical CO2. Royal Soc Chem. 2010. 5(86): 70101-70108.
• Rocha JHG, Lemos AF. Hydroxyapatite scaffolds hydrothermally grown from aragonitic cuttlefish bones. J Mater Chem. 2005. 15: 5007–5011.
• Rehman S, Khan K, Mujahid M, Nosheen S. Synthesis of Nano Hydroxyapatite and its Rapid Mediated Surface Functionalization by Silane Coupling Agent. Mat Sci Eng C Mater Biol Appl 2016. 675–681.
• Taşkın MB, Şahin Ö, Taşkın H, Atakol O, İnal A, Güneş A. Effect of synthetic nano-hydroxyapatite as an alternative phosphorus source on growth and phosphorus nutrition of lettuce (Lactuca sativa L.) plant. J Plant Nut. 2018. 41(9): 1148-1154.
• Maji R, ShekharDey N, Satapathy BS, Mukherjee B, Mondal S. Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. Inter J Nanomed. 2014. 9: 3107–3118.
• Nosrati H, Rashidi N, Danafar H, Manjili HK. Anticancer Activity of Tamoxifen Loaded Tyrosine Decorated Biocompatible Fe3O4 Magnetic Nanoparticles Against Breast Cancer Cell Lines. J Inorganic and Organomet Poly Mat. 2017. 28(3): 1178-1186.
• Bora DK, Rozhkova EA, Schrantz K, Wyss PP, Braun A, Graule T. Costable EC. Functionalization of Nanostructured Hematite Thin-Film Electrodes with the Light-Harvesting Membrane Protein C-Phycocyanin Yields an Enhanced Photocurrent. Adv Func Mat. 2012. 22: 490–502.
• Han L, Park SW, Park D. Silica grafted imidazolium-based ionic liquids: efficient heterogeneous catalysts for chemical fixation of CO2 to a cyclic carbonate. Energy Env Sci. 2009. 2: 1286–1292.
• Lazarevıć SS, Janković-Častvan IM, Jokić BM, Janaćković DT, Petrović RD. Sepiolite functionalized with N-[3(trimethoxysilyl)propyl]-ethylenediamine triacetic acid trisodium salt, Part I: Preparation and characterization, J Serb Chem Soc. 2015. 80(9): 1193–1202.
• Simek P, Klímová K, Sedmidubsky D, Jankovský O, Pumer M, Sofer Z. Towards graphene iodide: Iodination of graphite oxide. Nanoscale. 2015. 7(1): 261-270.
• Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX. Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent. Mater. 2010. 26(1): 51-58.
• Öztürk E, Karaboğa A, Dokumacı AH, Yerer MB. Real-time Analysis of Impedance Alterations by the Effects of Vanadium Pentoxide on Several Carcinoma Cell Lines. Turk J Pharm Sci. 2018. 15(1): 1-6.
• Hassan F, Mohammed G, Gamal A, El-Hiti GA, Alshanon A, Yousif E. Cytotoxic effects of tamoxifen in breast cancer cells. J Unexplored Med Data. 2018. 3 (3): 2-9.
• Khadka NK, Cheng X, Ho CS, Katsaras J, Pan J. Interactions of the anticancer drug tamoxifen with lipid membranes. Biophys J. 2015. 108 (10): 2492-2501.
• Huang H, Du M, Chen J, Zhong S, Wang J. Preparation and characterization of abalone shells derived biological mesoporous hydroxyapatite microspheres for drug delivery. Mat. Sci Eng C Mater Biol Appl 2020. 113:110969. doi.org/10.1016/j.msec.2020.110969.
• Wozniak K, Kolacinska A, Blasinska-Morawie M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, ,Blasiak J. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol (2007) 81:519–527 DOI 10.1007/s00204-007-0188-3.
• Melo MT, de Oliveria IM, Grivicich I, Guecheva TN, Saffi J, Henriques JAP, Rosa RM. Diphenyl diselenide protects cultured MCF-7 cells against tamoxifen-induced oxidative DNA damage. Biomed Pharma. 2013. 67(4): 329–335.
• Mondal S, Dorozhkin SV, Pal U. Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite. Nanomed Nanobiotech. 2018. 10 (4):1504.